AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20171421 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of clopidogrel 75-mg tablets
Number of subjects: 24
Study 18065851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling sessions (up to 6 sessions at 6-month intervals over 24 months)
Number of subjects: 231
Study 18065851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling sessions
Number of subjects: 231
Study 17763408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-sequential estrogen-progestogen regimen (n = 52)
Number of subjects: 106
Study 17763408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 106
Study 15370796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (3500 patients)
Number of subjects: 8135
Study 15370796 — intervention group
Group type: COMPARATOR
Intervention: Control group (4635 patients)
Number of subjects: 8135
Study 11118919 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 0.3 ml
Number of subjects: 220
Study 11118919 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 0.6 ml
Number of subjects: 220
Study 11118919 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 1.2 ml
Number of subjects: 220
Study 11118919 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (Bracco) 2.4 ml
Number of subjects: 220
Study 9096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 577
Study 9096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 577
Study 9096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 577
Study 9096977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study 1345034 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 38
Study 1345034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 38
Study 4048837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroduodenostomy (BI)
Number of subjects: 27
Study 4048837 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y diversion
Number of subjects: 27
Study 31818310 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy in addition to usual care
Number of subjects: 158
Study 31818310 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 158
Study 30264849 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises with a pelvic realignment device (group R, n=25)
Number of subjects: 75
Study 30264849 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise (group E, n=25)
Number of subjects: 75
Study 30264849 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n=25)
Number of subjects: 75
Study 27066903 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceval S valve implantation
Number of subjects: 25
Study 27066903 — intervention group
Group type: COMPARATOR
Intervention: Conventional stented biological prosthesis (Soprano LivaNova)
Number of subjects: 25
Study 24247740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 2
Study 24247740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 21565432 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone assessment
Number of subjects: 380
Study 21565432 — intervention group
Group type: COMPARATOR
Intervention: Direct contact assessment
Number of subjects: 380
Study 20158899 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing search strategy (randomized controlled trial.pt)
Number of subjects: 0
Study 20158899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined search strategy with cluster design-related terms using AND
Number of subjects: 0
Study 20158899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined search strategy with Boolean operator OR
Number of subjects: 0
Study 20158899 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual inspection of full-text articles
Number of subjects: 0
Study 20158899 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CRT identification over time
Number of subjects: 0
Study 17705082 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially expanding trocars
Number of subjects: 80
Study 17705082 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting trocars
Number of subjects: 80
Study 15740818 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 204
Study 11927522 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin
Number of subjects: 148
Study 11927522 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 148
Study 9445236 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bandage heated to 38 degrees C for 1 week
Number of subjects: 18
Study 9445236 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze bandage (control) applied to contralateral thigh
Number of subjects: 18
Study 8583233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 13
Study 8583233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8583233 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 13
Study 8583233 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 2653742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 28
Study 2653742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzepin
Number of subjects: 0
Study 6928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 31711219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with practice facilitators trained in improving practice-level BP control over 12 months (13 visits).
Number of subjects: 257
Study 29243519 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Number of subjects: 536
Study 29130588 — intervention group
Group type: EXPERIMENTAL
Intervention: HT042
Number of subjects: 129
Study 27836873 — intervention group
Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 460
Study 27836873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 460
Study 25246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly subjects
Number of subjects: 46
Study 25246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly males
Number of subjects: 46
Study 25246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly females
Number of subjects: 46
Study 25246162 — intervention group
Group type: COMPARATOR
Intervention: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in non-elderly subjects
Number of subjects: 46
Study 25246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST) 1.75 mg and 3.5 mg in elderly subjects
Number of subjects: 46
Study 25246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate tablet (ZST)
Number of subjects: 46
Study 21760473 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 20
Study 21760473 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily
Number of subjects: 20
Study 19641358 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin XL 10 mg once daily for 2 days
Number of subjects: 67
Study 19641358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative and pharmaceutical approaches for treatment of infection stones
Number of subjects: 0
Study 17726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphylactic treatment
Number of subjects: 0
Study 17726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis through urinalysis and urine culture
Number of subjects: 0
Study 17726350 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging techniques
Number of subjects: 0
Study 15894896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 420
Study 15894896 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 420
Study 12755527 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of recombinant Hepatitis B vaccine
Number of subjects: 99
Study 12755527 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of recombinant Hepatitis B vaccine
Number of subjects: 99
Study 10338107 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8g daily for 12 weeks
Number of subjects: 927
Study 10338107 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 12g intravenous bolus, 12g daily for 4 weeks, and 4.8g daily for a further 8 weeks
Number of subjects: 927
Study 10338107 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam treatment within 7 hours of stroke onset
Number of subjects: 927
Study 10338107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 8739658 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 144
Study 8739658 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 144
Study 1928712 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (200 IU/kg subcutaneously, 7 times starting 3 days after first blood withdrawal)
Number of subjects: 10
Study 1928712 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHuEPO treatment)
Number of subjects: 10
Study 1928712 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 10
Study 1928712 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 6804625 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Number of subjects: 0
Study 6804625 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 0
Study 30694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity PA (300 min·wk at 40%-59% of HR reserve)
Number of subjects: 45
Study 30694978 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity PA (150 min·wk at 60%-80% of HR reserve)
Number of subjects: 45
Study 30694978 — intervention group
Group type: COMPARATOR
Intervention: Control (no PA intervention)
Number of subjects: 45
Study 30213052 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-A (68 g fresh Hass avocado)
Number of subjects: 31
Study 30213052 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-A (136 g fresh Hass avocado)
Number of subjects: 31
Study 30213052 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g avocado)
Number of subjects: 31
Study 26795936 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week, Internet-based, cognitive-behavioral intervention
Number of subjects: 206
Study 26795936 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 206
Study 25179979 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally thoracoscopic surgery
Number of subjects: 254
Study 22323869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solubilized UDCA (3.5 g/140 mL/day)
Number of subjects: 63
Study 22323869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20661198 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 36
Study 20661198 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 36
Study 18179342 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational lectures
Number of subjects: 105
Study 18179342 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, clinician-based approach
Number of subjects: 105
Study 18179342 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 15857210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganopoly (polysaccharide extract of G. lucidum)
Number of subjects: 132
Study 15857210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12199869 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 16
Study 12199869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9475317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lung disease (CLD)
Number of subjects: 47
Study 9475317 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory distress syndrome (RDS)
Number of subjects: 47
Study 9475317 — intervention group
Group type: COMPARATOR
Intervention: Control babies
Number of subjects: 47
Study 7715468 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice intake
Number of subjects: 8
Study 7715468 — intervention group
Group type: COMPARATOR
Intervention: No grapefruit juice intake (control)
Number of subjects: 8
Study 3296876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 104
Study 3296876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 104
Study 3296876 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Lidocaine and Bupivacaine
Number of subjects: 104
Study 30114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy model in occupational rehabilitation programme
Number of subjects: 22
Study 30114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic approach
Number of subjects: 22
Study 30114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Number of subjects: 22
Study 30420682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 49
Study 30420682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 26016834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program of moderate intensity (3 sessions/week on a bicycle at 60-70% VO2peak for 3 months, followed by one session/week until 1-year follow-up)
Number of subjects: 51
Study 26016834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 51
Study 26016834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal ET)
Number of subjects: 51
Study 24781718 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayShield™ Adhesion Barrier
Number of subjects: 15
Study 24781718 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-adhesion treatment)
Number of subjects: 15
Study 23097096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg) administered intravenously in three doses, eight hours apart
Number of subjects: 34
Study 23097096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19108988 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 6105
Study 19108988 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 6105
Study 17209672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 17209672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus statin
Number of subjects: 0
Study 15164294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis players with tournament experience
Number of subjects: 110
Study 15164294 — intervention group
Group type: COMPARATOR
Intervention: Tennis players without tournament experience
Number of subjects: 110
Study 11222469 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1220
Study 11222469 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 1220
Study 11222469 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting) among diabetic patients
Number of subjects: 1220
Study 11222469 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty) among diabetic patients
Number of subjects: 1220
Study 9556238 — intervention group
Group type: EXPERIMENTAL
Intervention: Parks hemorrhoidectomy
Number of subjects: 34
Study 9556238 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 34
Study 7528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TUR-P)
Number of subjects: 0
Study 7528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Open prostatectomy
Number of subjects: 0
Study 7528405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate
Number of subjects: 0
Study 7528405 — intervention group
Group type: COMPARATOR
Intervention: Newer less invasive procedures
Number of subjects: 0
Study 3415889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 20 ml h‐1 (in saline)
Number of subjects: 20
Study 3415889 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 20
Study 8498894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 2
Study 8498894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 42224 — intervention group
Group type: EXPERIMENTAL
Intervention: mepindolol-sulfate (2 x 2.5 mg)
Number of subjects: 20
Study 31787433 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated (HC) circuits
Number of subjects: 26
Study 31787433 — intervention group
Group type: COMPARATOR
Intervention: Nonheparin phosphorylcholine-coated (PC) circuits
Number of subjects: 26
Study 31445354 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab (800 mg) with nab-paclitaxel (100 mg/m2) and carboplatin (AUC 6 mg*min/mL) for 4 cycles, followed by necitumumab and nab-paclitaxel maintenance
Number of subjects: 54
Study 29234057 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (2g daily for 12 weeks)
Number of subjects: 24
Study 29234057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25794457 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG induction followed by one BCG instillation every 3 months for 3 years (maintenance arm)
Number of subjects: 397
Study 25794457 — intervention group
Group type: COMPARATOR
Intervention: BCG induction alone (no-maintenance arm)
Number of subjects: 397
Study 23401618 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 administration during the last 7 days of GnRHant
Number of subjects: 14
Study 23401618 — intervention group
Group type: COMPARATOR
Intervention: GnRHant
Number of subjects: 14
Study 23401618 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 administration
Number of subjects: 14
Study 23401618 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal LBNP
Number of subjects: 14
Study 20549247 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h method
Number of subjects: 90
Study 20549247 — intervention group
Group type: COMPARATOR
Intervention: 6-h method
Number of subjects: 90
Study 19483223 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin adhesive
Number of subjects: 90
Study 19483223 — intervention group
Group type: COMPARATOR
Intervention: Surgical staples
Number of subjects: 90
Study 17182820 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise, 45 min/d, 5 d/wk for 1 year
Number of subjects: 0
Study 17182820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention of 60 min/d, 6 d/wk for 1 year
Number of subjects: 0
Study 17182820 — intervention group
Group type: COMPARATOR
Intervention: Low-fat dietary pattern for 8-12 years
Number of subjects: 0
Study 15955900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016) administered once daily at doses ranging from 500 to 1,600 mg
Number of subjects: 67
Study 11449341 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg once daily for 6 to 14 days
Number of subjects: 0
Study 11449341 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9249964 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional use of 'blue' and 'yellow' groups assigned on the basis of a biological attribute
Number of subjects: 61
Study 9249964 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional use of 'blue' and 'yellow' groups assigned on the basis of a random drawing
Number of subjects: 61
Study 9249964 — intervention group
Group type: COMPARATOR
Intervention: No explicit groups (despite the presence of blue and yellow groups)
Number of subjects: 61
Study 9249964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of self-esteem
Number of subjects: 61
Study 7951125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice a day plus antifungal prophylaxis (fluconazole 50 mg once daily plus amphotericin B 200 mg four times a day) and streptococcal prophylaxis for 10 days after BMT
Number of subjects: 113
Study 7951125 — intervention group
Group type: COMPARATOR
Intervention: Protective isolation
Number of subjects: 113
Study 31402293 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 units VitD3 capsules every week for 7 weeks
Number of subjects: 100
Study 31402293 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 300,000 units VitD3 ampoule
Number of subjects: 100
Study 31402293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of half of the injection dose followed by oral capsule for 4 weeks
Number of subjects: 100
Study 28597922 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg DFN-02
Number of subjects: 18
Study 28597922 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DFN-02
Number of subjects: 18
Study 28597922 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg DFN-02
Number of subjects: 18
Study 28597922 — intervention group
Group type: COMPARATOR
Intervention: 6 mg subcutaneous sumatriptan injection
Number of subjects: 18
Study 25204557 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral lenvatinib (5 mg for severe hepatic impairment)
Number of subjects: 26
Study 22901697 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlife hypertension
Number of subjects: 63
Study 22901697 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous decline in systolic BP and increase in pulse pressure
Number of subjects: 63